Profile data is unavailable for this security.
About the company
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications with high unmet need. Its advanced programs are APG777 and APG808, which are developed for the treatment of AD and COPD, respectively. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. APG808 is an SQ extended half-life mAb targeting IL-4Rα. Its earlier-stage programs, APG990 and APG222, utilize advanced antibody engineering to target OX40L and both IL-13 and OX40L, which are developed for the treatment of AD. APG990 is an SQ extended half-life mAb targeting OX40L for the treatment of AD. APG222 is one or more extended half-life SQ antibodies targeting both IL-13 and OX40L, which has the potential to improve outcomes in AD.
- Revenue in USD (TTM)0.00
- Net income in USD-103.55m
- Incorporated2023
- Employees91.00
- LocationApogee Therapeutics Inc221 Crescent St.Building 17, Suite 102bWALTHAM 02453United StatesUSA
- Phone+1 (650) 394-5230
- Fax+1 (302) 655-5049
- Websitehttps://apogeetherapeutics.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PTC Therapeutics, Inc. | 927.56m | -579.22m | 2.61bn | 988.00 | -- | -- | -- | 2.82 | -7.69 | -7.69 | 12.28 | -11.66 | 0.5459 | 2.33 | 4.64 | 938,823.90 | -34.09 | -26.71 | -48.63 | -33.46 | 92.88 | 93.94 | -62.45 | -83.80 | 1.98 | -0.8357 | 1.72 | -- | 34.20 | 28.78 | -12.09 | -- | 32.00 | -- |
Beam Therapeutics Inc | 360.91m | -134.74m | 2.73bn | 436.00 | -- | 2.99 | -- | 7.56 | -1.74 | -1.74 | 4.54 | 11.10 | 0.2681 | -- | -- | 827,777.50 | -10.01 | -24.54 | -11.79 | -29.26 | -- | -- | -37.33 | -211.96 | -- | -- | 0.00 | -- | 520.01 | -- | 54.16 | -- | 20.78 | -- |
Agios Pharmaceuticals Inc | 29.40m | -352.62m | 2.73bn | 383.00 | -- | 3.67 | -- | 92.78 | -6.31 | -6.31 | 0.5257 | 13.11 | 0.0294 | 0.1715 | 11.24 | 76,770.23 | -35.24 | -29.54 | -37.04 | -31.88 | 89.95 | -- | -1,199.26 | -3,826.10 | 12.39 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
Kymera Therapeutics Inc | 79.41m | -154.59m | 2.73bn | 186.00 | -- | 3.84 | -- | 34.41 | -2.50 | -2.50 | 1.29 | 11.59 | 0.1072 | -- | 29.69 | 424,668.40 | -20.86 | -23.03 | -22.67 | -27.64 | -- | -- | -194.67 | -207.82 | -- | -- | 0.0032 | -- | 67.84 | -- | 5.07 | -- | 91.01 | -- |
Geron Corp | 520.00k | -201.40m | 2.76bn | 141.00 | -- | 7.93 | -- | 5,315.38 | -0.3464 | -0.3464 | 0.0009 | 0.5876 | 0.0012 | -- | 0.3225 | 3,687.94 | -44.41 | -51.32 | -54.44 | -64.90 | -- | -- | -38,729.81 | -19,949.13 | -- | -- | 0.1935 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
SpringWorks Therapeutics Inc | 26.45m | -339.07m | 2.82bn | 305.00 | -- | 4.96 | -- | 106.54 | -5.15 | -5.15 | 0.4007 | 7.66 | 0.0432 | -- | -- | 86,731.15 | -55.31 | -36.97 | -60.58 | -39.49 | 93.86 | -- | -1,281.78 | -2,176.46 | 6.77 | -- | 0.00 | -- | -- | -- | -17.19 | -- | 90.68 | -- |
Morphic Holding Inc | 0.00 | -179.83m | 2.84bn | 128.00 | -- | 4.58 | -- | -- | -3.72 | -3.72 | 0.00 | 12.34 | 0.00 | -- | -- | 0.00 | -25.79 | -22.69 | -26.63 | -24.99 | -- | -- | -- | -258.10 | -- | -- | 0.00 | -- | -99.26 | -31.11 | -157.61 | -- | 13.50 | -- |
MoonLake Immunotherapeutics | 0.00 | -40.68m | 2.86bn | 50.00 | -- | 5.19 | -- | -- | -0.7501 | -0.7501 | 0.00 | 8.63 | 0.00 | -- | -- | 0.00 | -14.53 | -- | -15.60 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
Apogee Therapeutics Inc | 0.00 | -103.55m | 2.92bn | 91.00 | -- | 3.51 | -- | -- | -2.04 | -2.04 | 0.00 | 14.22 | 0.00 | -- | -- | 0.00 | -21.45 | -- | -22.20 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
Celldex Therapeutics, Inc. | 6.07m | -144.88m | 2.94bn | 160.00 | -- | 3.50 | -- | 483.69 | -2.84 | -2.84 | 0.1182 | 12.72 | 0.0102 | -- | 3.05 | 37,950.00 | -24.28 | -29.65 | -25.16 | -31.42 | -- | -- | -2,385.97 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
Rhythm Pharmaceuticals Inc | 91.93m | -273.87m | 2.99bn | 226.00 | -- | 48.56 | -- | 32.53 | -4.62 | -4.62 | 1.57 | 1.01 | 0.3042 | 1.53 | 8.06 | 406,747.80 | -90.64 | -47.21 | -108.65 | -52.84 | 88.37 | -- | -297.93 | -681.38 | 4.20 | -139.42 | 0.6355 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
Amicus Therapeutics, Inc. | 423.49m | -147.07m | 3.02bn | 517.00 | -- | 23.07 | -- | 7.12 | -0.493 | -0.493 | 1.42 | 0.4413 | 0.5955 | 1.00 | 5.86 | 819,127.70 | -20.68 | -30.65 | -25.76 | -36.55 | 89.62 | 88.94 | -34.73 | -86.10 | 2.61 | -1.36 | 0.7482 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
ACADIA Pharmaceuticals Inc | 813.81m | -1.71m | 3.16bn | 610.00 | -- | 6.80 | 353.57 | 3.89 | -0.0129 | -0.0129 | 4.93 | 2.81 | 1.08 | 1.85 | 10.13 | 1,363,159.00 | -0.2264 | -27.50 | -0.3579 | -32.73 | 92.27 | 95.62 | -0.2101 | -38.35 | 1.86 | -- | 0.00 | -- | 40.45 | 26.55 | 71.62 | -- | 79.52 | -- |
TG Therapeutics Inc | 289.33m | 41.20m | 3.18bn | 284.00 | 93.27 | 19.85 | 76.83 | 10.98 | 0.2205 | 0.2205 | 1.97 | 1.04 | 1.01 | 0.3567 | 7.86 | 1,095,962.00 | 14.44 | -62.87 | 20.20 | -80.06 | 93.53 | -- | 14.24 | -405.03 | 2.84 | 4.01 | 0.3876 | -- | 8,290.02 | 333.86 | 106.39 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 6.26m | 13.92% |
Perceptive Advisors LLCas of 31 Mar 2024 | 2.70m | 6.00% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 2.55m | 5.67% |
RTW Investments LPas of 31 Mar 2024 | 2.47m | 5.49% |
Deep Track Capital LPas of 31 Mar 2024 | 2.32m | 5.17% |
Wellington Management Co. LLPas of 31 Mar 2024 | 2.23m | 4.96% |
Driehaus Capital Management LLCas of 31 Mar 2024 | 2.06m | 4.59% |
Fairmount Funds Management LLCas of 31 Mar 2024 | 2.05m | 4.56% |
RA Capital Management LPas of 31 Mar 2024 | 1.98m | 4.40% |
Braidwell LPas of 31 Mar 2024 | 1.84m | 4.10% |